Eikonoklastes Therapeutics

Eikonoklastes Therapeutics is a preclinical-stage biopharmaceutical company advancing a new generation of tissue factor (TF) immunotherapies for the treatment of triple-negative breast cancer and a wide range of other diseases with high incidence and significant unmet clinical needs. The company effectively targets three key components of the tumor microenvironment (tumor cells, abnormal neovasculature, and cancer stem cells) by activating the body's natural immune system without harming normal cells.